SEC Form 4 · accession 0001209191-17-033918
ENDRA Life Sciences Inc. · NDRA
Statement of changes in beneficial ownership, as filed. Original on EDGAR ↗
A later amendment supersedes this filing — read the amendment. The figures below are kept as originally reported (version chain, not an overwrite).
Reporting owner
Anthony Digiandomenico
Director
Period of report
May 12, 2017
Accepted (ET)
May 19, 2017 · 4:07 pm EDT
Rule 10b5-1 plan
unknown — predates the checkbox
Issuer CIK
0001681682
Table I — non-derivative securities
| Security | Date | Code | Shares | Price | A/D | Owned after | D/I | Nature of ownership |
|---|---|---|---|---|---|---|---|---|
| Common StockF1 | May 12, 2017 | C | 19,426 | $1.40 | A | 58,625 | D |
Table II — derivative securities
| Security | Conv. / exercise price | Date | Code | Shares | A/D | Exercisable | Expires | Underlying | Underlying shares | Owned after | D/I |
|---|---|---|---|---|---|---|---|---|---|---|---|
| Convertible Promissory NoteF2 | $1.40 | May 12, 2017 | C | — | D | — | May 12, 2017 | Common Stock | — | — | D |
| Stock Options | $5.00 | May 12, 2017 | A | 12,000 | A | May 12, 2017 | May 12, 2022 | Common Stock | 12,000 | 12,000 | D |
Explanation of responses
- F1These shares of Common Stock were issued upon the conversion of the Convertible Promissory Note, as described in footnote (2).
- F2The principal amount of, and accrued interest on, the Convertible Promissory Note converted into shares of Common Stock of the Issuer at a conversion price of $1.40 per share immediately prior to the consummation of the Issuer's initial public offering.